<DOC>
	<DOCNO>NCT02209441</DOCNO>
	<brief_summary>- To determine maximum-tolerated dose ( MTD ) dose-limiting toxicity ( DLT ) sorafenib combination FOLFOX4 ( oxaliplatin/leucovorin/5-fluorouracil ) first-line treatment advance gastric cancer - The design study incorporate standard 3 + 3 dose escalation procedure guide elevation sorafenib dosage next level</brief_summary>
	<brief_title>Phase I Study Sorafinib With Folfox4 First-line Treatment Advanced/Metastatic Gastric Cancer</brief_title>
	<detailed_description>-Twice-daily dose sorafenib 200 mg combination FOLFOX4 prove effective safe treatment advance gastric cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>age &gt; 18 year . document gastric adenocarcinoma via histological cytological examination ; newly diagnose recurrent unresectable advanced metastatic gastric cancer ; history chemotherapy radiation therapy ; least one lesion measurable diameter ; Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 ; expect survival time least 3 month ; provision inform consent patient prior commencement study . present past medical history tumor , except cure skin cancer ( nonmelanoma ) carcinoma situ cervix ; surgery , open biopsy , obvious trauma within 28 day prior enrolment ; peritoneal seed intestinal obstruction ; severe gastrointestinal bleeding ; grade 1 great peripheral neuropathy past medical history serious neurological psychiatric disease ; pregnancy lactation ; woman childbearing potential unwilling use adequate contraception ; past medical history heart disease great grade 2 New York Heart Association ( NYHA ) congestive heart failure , unstable coronary heart disease ( patient episodes myocardial infarction earlier 12 month prior study allow enrol ) , arrhythmia require antiarrhythmic therapy ( patient Î²blockers digoxin allow enrol ) , uncontrolled hypertension ; severe active infection epileptic patient require medical treatment ( corticosteroid antiepileptic drug ) ; patient receive immunotherapy within 4 week prior throughout study receive mitomycin C nitrourea drug within 4 week previously ; allergy possible allergy study medication drug administer study ; patient safety compliance issue might jeopardize participation study ; inability swallow oral drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>sorafenib , gastric cancer , FOLFOX4</keyword>
</DOC>